Equities research analysts at StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research report issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Stock Down 1.2 %
AKTX opened at $2.52 on Thursday. The stock’s 50 day moving average price is $3.28 and its 200-day moving average price is $2.70. Akari Therapeutics has a one year low of $1.08 and a one year high of $4.40.
About Akari Therapeutics
Further Reading
- Five stocks we like better than Akari Therapeutics
- What is the S&P 500 and How It is Distinct from Other Indexes
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- Quiet Period Expirations Explained
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.